Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Similar
Filing Names

Institut Pasteur
Institut Pasteur De Lille
Institut Pasteur Korea
Institut Pasteur Of Shanghai Chinese Academy Of Sciences
Institut Pasteur And Centre National De La Recherche Scientifique
Institut Pasteur De Lille ipl
Institut Pasteur And Inserm
Institut Pasteur And Institut Nationale De La Recherche Medicale
Institut Pasteur And Centre Nationale De La Recherche Scientifique
Institut Pasteur Of Shanghai Cas
Institut Pasteur And Centre De La Recherche Scientifique
Institut Pasteur And Centre National De La Recherche Scientifique cnrs
Institut Pasteur And The Centre National De La Recherche Scientifique cnrs
Institut Pasteur Centre National De La Recherche Scientifique And Universite Paris
Institut Pasteur De Tunis
Institut Pasteur Du Cambodge
Institut Pasteur_20100114
Institut Pasteur Of Shanghai
Institut Pasteur Centre National De La Recherche Scientifique
Institut Pasteur Institut National De La Sante Et De La Recherche Medicale x26 Assistance Publique

Institut Pasteur patents


Recent patent applications related to Institut Pasteur. Institut Pasteur is listed as an Agent/Assignee. Note: Institut Pasteur may have other listings under different names/spellings. We're not affiliated with Institut Pasteur, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Institut Pasteur-related inventors


 new patent  Rna virus attenuation by alteration of mutational robustness and sequence space

The application generally relates to the attenuation of a RNA virus or of a clone thereof and involves the alteration of sequence space, more particularly the reduction, of mutational robustness of said RNA virus or clone. The means of the application are more particularly dedicated to the attenuation of an... Institut Pasteur

Adam12 inhibitors and their use against inflammation-induced fibrosis

The present invention relates to the field of fibrosis and inflammation and more particularly to the use of ADAM12 (A Disintegrin and Metalloproteinase 12) inhibitors to prevent or treat inflammation-induced fibrosis. The present invention also relates to the use of ADAM12 as a marker for inflammation-induced fibrosis and to the... Institut Pasteur

Antiviral agents directed against respiratory syncytial virus

The present invention relates to N1-benzyl substituted pyrazoles as antiviral agents directed against respiratory syncytial virus.... Institut Pasteur

Use of non-subtype b gag proteins for lentiviral packaging

The invention encompasses a lentiviral packaging vector comprising a non-subtype B gag-pol sequence, particularly a subtype D gag-pol sequence. The invention further encompasses methods for making and using these vectors. The invention further encompasses lentiviral vector particles comprising HIV-1 non-subtype B Gag and/or Pol proteins.... Institut Pasteur

Methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (hiv-1) infections

The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1... Institut Pasteur

Polyclonal antibodies specific for serogroup x of n. meningitidis and uses thereof in diagnosis

Polyclonal antibodies specific for serogroup X of N. meningitidis and uses thereof in diagnosis. The present invention is directed to polyclonal antibodies, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X in biological fluids... Institut Pasteur

Method of culturing segmented filamentous bacteria in vitro

The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium... Institut Pasteur

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological... Institut Pasteur

Conjugated molecules comprising a peptide derived from the cd4 receptor coupled to an anionic polypeptide for the treatment of aids

This invention relates to a conjugated molecule comprising a peptide derived from the CD4 receptor coupled to an organic molecule by means of a linker as well as a process for its preparation. Said organic molecule comprises a 5 to 21 amino acid anionic polypeptide. Such a conjugated molecule can... Institut Pasteur

Lentiviral vector-based japanese encephalitis immunogenic composition

The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention... Institut Pasteur

Nod2-dependent pathway of cytoprotection of stem cells

The present invention is directed to an agonist of NOD2 for use in therapy for increasing the autonomous capacity of survival of vertebrate adult stem cells, without loss of their capacity to multiply and differentiate, and preferably the capacity of survival of intestinal stem cells, especially in response to a... Institut Pasteur

Polynucleotides encoding mhc class i-restricted htert epitopes, analogues thereof or polyepitopes

This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also... Institut Pasteur

Use of leptospira fainei serovar hurstbridge bacteria for diagnosing leptospirosis

The present invention discloses an in vitro method for diagnosing a Leptospira infection in a biological sample of a subject, comprising a step of contacting said sample with bacterial cells of a serovar of the Leptospira fainei species, preferably bacterial cells of the Leptospira fainei serovar Hurstbridge, or an antigenic... Institut Pasteur

Method for preparing multiple antigen glycopeptide carbohydrate conjugates

The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n (I) wherein M, T, B and n ore as defined in claim 1.... Institut Pasteur

Nanobodies suitable for neuron regeneration therapy

The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of... Institut Pasteur

Multiplex immuno screening assay

The present invention provides kits and assay methods for the early detection of pathogens, precise identification of the etiologic agent, and improved disease surveillance. More specifically, the present invention discloses an immunoassay leading to the rapid and simultaneous detection of antibodies to a wide range of infectious pathogens in biological... Institut Pasteur

Levels of cxcl10/ip-10 forms and soluble cd26/dppiv activity as early predictive biomarkers for hiv/siv associated mucosal inflammation and progression towards aids

The invention provides methods for the identification of patients capable of controlling HIV progression, as well as to the identification of an antagonist form of IP-10 associated to HIV progression control and the uses thereof for improving the immunological response of HIV patients.... Institut Pasteur

Insecticide properties of an extract of sextonia rubra, and the constituents thereof

The invention relates to the use of an extract of Sextonia rubra or the constituents thereof, rubrenolide and/or rubry-nolide, as an insecticide agent against mosquitoes, especially as a larvicide agent.... Institut Pasteur

New in vitro blood-brain barrier model

The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of... Institut Pasteur

Methods for in vitro investigating mitochondrial replication dysfunction in a biological sample, kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptomes and screening identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s)

The invention relates to a method for in vitro investigating mitochondrial replication dysfunction in a biological sample removed from a subject susceptible of suffering from physiological ageing or physiopathological conditions related to physiological ageing, or physiopathological ageing or associated symptoms or conditions, in particular premature ageing or accelerated ageing, or... Institut Pasteur

Predictive value of clostridium difficile-specific immune response for recurrence and disease outcome

The present invention relates to the field of Clostridium difficile infections. Methods of diagnosing, treating and preventing Clostridium difficile-associated disease and recurrent CDAD are disclosed herein.... Institut Pasteur

Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins

The present invention relates to the use of variable domains of camelid heavy-chain antibodies (VHH domains) directed against an intracellular target and having an isoelectric point of at least 8.5, for targeting said intracellular target or for the preparation of a peptide vector. Particularly, it concerns VHH domains directed against... Institut Pasteur

Ob-fold used as scaffold for engineering new specific binders

The present invention pertains to the field of protein engineering, and provides means for obtaining stable molecules that specifically bind to a target selected amongst a large variety of ligands families. In particular, the present invention provides methods for obtaining a molecule specifically binding to a target of interest, through... Institut Pasteur

Method, device, and computer program for assembling pieces of chromosomes from one or several organisms

A method of assembling a sequence representing pieces of at least one chromosome from a set of raw sub-sequences representing DNA fragments of a library including DNA fragments including chains of contiguous nucleotides and including DNA fragments including combinations of at least two chains of contiguous nucleotides. After having obtained... Institut Pasteur

A dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection

The present invention is directed to a dengue virus chimeric polyepitope composed of fragments of non-structural proteins and its use in an immunogenic composition against dengue virus infection. The present invention provides means, in particular polynucleotides, vectors, cells and methods to produce vectors expressing said chimeric polyepitopes, in particular vectors... Institut Pasteur

Chimeric poly peptides and the therapeutic use thereof against a flaviviridae infection

The invention relates to building a chimeric polypeptide used for preventing or treating a Flaviviridae infection. The use of the inventive chimeric polypeptide for producing recombinant viral vectors such as a measles living viral vector is also disclosed.... Institut Pasteur

Recombinant mycobacterium bovis bcg expressing antigens of the mycobacterium marinum esx-1 secretion system

Recombinant strains of Mycobacterium bovis bacille Calmette-Guerin (M. bovis BCG) comprising a heterologous nucleic acid sequence of Mycobacterium marinum (M. marinum) are provided. In some embodiments the heterologous nucleic acid sequence of M. marinum comprises a plurality of open reading frames, wherein the plurality of open reading frames comprise open... Institut Pasteur

Broad range gene and genotype papillomavirus transcriptome as a biomarker of papillomavirus-associated cancer stages

The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections... Institut Pasteur

Enzyme-independent photon emission

The invention relates to a new method for generating a luminescent signal, which is based on an enzyme-independent photon emission mechanism (EiPE), whereby luminescent light is generated when a bioluminescent substrate interact with a physical surface in the absence of any catalytic enzyme. In particular embodiments, the method is used... Institut Pasteur

Methods for obtaining stem cells

The present invention relates to methods for obtaining stem cells from mammalian cadavers, methods for obtaining or purifying stem cells from a sample likely to contain non-stem cells, methods of regeneration of injured tissues and methods of treatment.... Institut Pasteur

Mgmt-based obtaining high yeilds of recombinant protein expression

The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding a) a secretion peptidic signal, b) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.1.63), a mutant or a catalytic domain thereof, and... Institut Pasteur

Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications

The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse... Institut Pasteur

Production of 1-propanol

This invention encompasses methods of making 1-propanol. In some embodiments the methods comprise providing a cultured bacterial biofilm; culturing the bacterial biofilm under conditions suitable for production of 1-propanol; and collecting 1-propanol produced by the biofilm culture. In some embodiments the methods comprise providing a bacterial culture comprising bacteria and... Institut Pasteur

Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof

The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as... Institut Pasteur

Method and device for conserving viable and functional human polymorphonuclear neutrophils

A method for keeping leukocytes alive ex vivo or in vitro, comprising maintaining the leukocytes in a medium comprising from 3 to 10 mM of glucose, in hypoxic conditions with P(02)≦10 mM Hg.... Institut Pasteur

02/23/17 / #20170052181

Rapid detection of the "high virulent" st-17 clone of group b streptococcus

The present invention also relates to kits and methods for the specific detection of Group B Streptococcus highly-virulent ST-17 clones, using the polynucleotides, the polypeptides or the antibodies according to the invention.... Institut Pasteur

02/09/17 / #20170037434

Chromosomal modification involving the induction of double-stranded dna cleavage and homologous recombination at the cleavage site

Methods of modifying, repairing, attenuating and inactivating a gene or other chromosomal DNA in a cell are disclosed. Also disclosed are methods of treating or prophylaxis of a genetic disease in an individual in need thereof. Further disclosed are chimeric restriction endonucleases.... Institut Pasteur

02/02/17 / #20170029794

Tal effector means useful for partial or full deletion of dna tandem repeats

The application relates to means, which derive from TAL effectors and TALENs. The structure of the means of the application is especially adapted for partial or full deletion of at least one DNA tandem repeat, more particularly for partial or full deletion of at least one DNA tandem repeat in... Institut Pasteur

01/26/17 / #20170021004

Leptospira immunoprotective proteins and methods of identification and use thereof

The present invention provides compositions and methods for eliciting heterologous protective immunity in animals against Leptospira spp. The Leptospira spp. immunoprotective peptides disclosed herein elicit protective immunity against subsequent challenge or exposure to at least two Leptospira spp. serovars.... Institut Pasteur

01/26/17 / #20170022567

High mast2-affinity polypeptides and uses thereof

The invention relates to polypeptides containing a cytoplasmic domain ending with a MAST-2 binding domain, from 11 to 13 residues, the first two residues of which are S and W, and the last four residues of which are Q, T, R and L, the polypeptides presenting a high affinity for... Institut Pasteur

01/05/17 / #20170002065

Use of vhh antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications

Use of a variable fragment (VHH antibody) of a camelid single-chain antibody for the preparation of a peptide vector for delivering a substance of interest across the blood-brain barrier or into a cell.... Institut Pasteur

07/06/17 / #20170189496

Use of phosphorylation pathway-related factor in regulating function of regulatory t cell

A method for the treatment and/or the prevention of a disease or a symptom related to dysfunction of regulatory T cell immunomodulation includes administering to a subject in need thereof compositions that regulate regulatory T cell immunomodulatory function, in which the compositions may be prepared by contacting starting materials with... Institut Pasteur

06/15/17 / #20170166563

2-amino-benzimidazole derivatives and their use as 5-lipoxygenase and/or prostaglandin e synthase inhibitors

The present invention relates to benzimidazole derivatives having the general formula I, wherein n is 0 or 1; X1 and X2 are independently, at each occurrence, CR5 or N; Y is C1-C6 alkylene, wherein alkylene is optionally substituted with one to two C1-C3 alkyl groups; R1 is selected from the... Institut Pasteur

05/04/17 / #20170121349

Anti-infective compounds

The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.... Institut Pasteur

02/16/17 / #20170044181

Compounds for treating viral infections

The present invention relates to small molecule compounds and their use in the treatment of diseases, in particular viral diseases, in particular hepatitis C virus (HCV).... Institut Pasteur

01/11/18 / #20180008723

 new patent  Multimeric compounds of a kringle domain from the hepatocyte growth factor / scatter factor (hgf/sf)

Disclosed are multimeric compounds of K1 domains from the Hepatocyte Growth Factor/Scatter Factor (HGF/SF) being able to induce activation of the tyrosine kinase receptor MET and their uses.... Institut Pasteur

12/28/17 / #20170369545

Met receptor agonist proteins

Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors,... Institut Pasteur

12/14/17 / #20170354709

Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a... Institut Pasteur

11/16/17 / #20170327572

Treatment of acute exacerbations of chronic obstructive pulmonary disease by antagonism of the il-20r

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a... Institut Pasteur

10/12/17 / #20170290903

Attenuated bordetella strains

A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of... Institut Pasteur

10/05/17 / #20170283890

Mutant bordetella strains and methods of use

A method of reducing or preventing the development of airway inflammation in a subject includes the step of infecting the respiratory tract of a subject an amount of a composition including a pharmaceutically acceptable carrier and live attenuated pertactin-deficient Bordetella bacteria sufficient to colonize the respiratory tract of the subject.... Institut Pasteur

07/27/17 / #20170210710

2-oxo-3,4-dihydropyridine-5-carboxylates and their use

The present invention is directed to novel compounds of Formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.... Institut Pasteur

07/20/17 / #20170202944

Prevention of pertussis using adenylate cyclase deficient bordetella strains

A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.... Institut Pasteur

07/06/17 / #20170190687

Imidazol- or 1,2,4-triazol-derivatives and their use

The present invention is directed to novel compounds of formula (I), pharmaceutically acceptable salts or solvates thereof, and their use.... Institut Pasteur

06/29/17 / #20170182077

Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease

The present invention relates to methods and pharmaceutical compositions for the treatment of acute exacerbation of chronic obstructive pulmonary disease. In particular, the present invention relates to a method of treating acute exacerbation of chronic obstructive pulmonary disease in a subject in need thereof comprising administering the subject with a... Institut Pasteur

04/20/17 / #20170106074

Influenza vaccine, composition, and methods of use

The invention relates to compositions and vaccines that include a mutated Bordetella strain for treating or preventing an influenza infection in a mammal. In addition, the invention further provides methods for protecting a mammal against infection by influenza and/or eliciting an immune response against an influenza virus in a mammal... Institut Pasteur

01/26/17 / #20170021015

Novel immunoadjuvant flagellin-based compounds and use thereof

The present invention relates to novel peptide compounds derived from flagellin originating from Salmonelle enterica that exhibit an in vivo immune adjuvant activity.... Institut Pasteur

07/20/17 / #20170204145

Anti-inflammatory properties of a surface protein of propionibacterium freudenreichii

Disclosed is a polypeptide including or consisting of the amino acid sequence SEQ id no:1, for use in the treatment or prevention of an inflammatory disease. It further encompasses a nucleic acid sequence encoding a polypeptide, a vector including a nucleic acid and a host cell including a nucleic acid... Institut Pasteur

04/27/17 / #20170114409

Mitochondrial non-coding rnas for predicting disease progression in heart failure and myocardial infarction patients

The present invention relates to a method for predicting mortality of a test patient with chronic heart failure comprising based on detecting the expression level of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 8. The present invention also relates to a method for... Institut Pasteur








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Institut Pasteur in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Institut Pasteur with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###